Similar articles

• Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

  Archer SL, Michelakis ED. Archer SL, et al. N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473. N Engl J Med. 2009. PMID: 19890129 Review. No abstract available.
• Phosphodiesterase inhibitors for pulmonary hypertension.

  Galiè N, Rubin LJ, Simonneau G. Galiè N, et al. N Engl J Med. 2010 Feb 11;362(6):559-60; author reply 560. N Engl J Med. 2010. PMID: 20175298 No abstract available.
• Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

  Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O. Montani D, et al. Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Adv Ther. 2009. PMID: 19768639 Review.
• Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.

  Semigran MJ. Semigran MJ. Circ Heart Fail. 2008 Nov;1(4):211-2. doi: 10.1161/CIRCHEARTFAILURE.108.830570. Circ Heart Fail. 2008. PMID: 19808293 No abstract available.
• Preoperative administration of PDE-5 Inhibitors.

  Edwards AF, Roy RC. Edwards AF, et al. J Clin Anesth. 2009 Mar;21(2):149; author reply 149-50. doi: 10.1016/j.jclinane.2009.01.001. J Clin Anesth. 2009. PMID: 19329023 No abstract available.